Aoxin Q & M Dental Group outlines growth plans and governance measures in pre-AGM reply to SIAS

SGX Filings
04/26

Aoxin Q & M Dental Group Limited has released detailed responses to queries from the Securities Investors Association (Singapore) ahead of its annual general meeting scheduled for Apr, 27 2026.

The board said the group, which currently operates 14 dental hospitals and polyclinics in Liaoning Province, still views expansion beyond the province as a “medium- to long-term” goal and is evaluating suitable acquisition targets. Management is conducting full due-diligence on a non-binding proposal signed on Mar, 25 2026 to acquire a China-based dental chain and medical-device business for about 28 million Singapore dollars.

Directors said they have tightened disclosure controls and information-barrier protocols after a series of March announcements that included a share placement, its upsizing, the closure of the Panjin Hospital and the proposed acquisition. The panjin facility’s shutdown was disclosed once the decision was finalised; its financial impact was assessed to be immaterial relative to group results, the board added.

Regarding a regulator-led review of national medical insurance claims, the company said two hospitals refunded roughly 0.7 million Singapore dollars in excess material-cost claims identified during a self-assessment. The board attributed the issue to differing interpretations of evolving guidelines but reported steps have been taken to standardise billing processes and strengthen compliance across the group.

The company also addressed upcoming board changes: long-serving chairman Chua Ser Miang will be re-designated as a non-independent chairman after exceeding the nine-year limit for independent directors, while two other independent directors will retire at the Apr, 27 2026 AGM. The nominating committee is conducting due diligence on one new independent-director candidate and is searching for another to maintain board independence in line with governance codes.

Management acknowledged the group’s weak shareholder returns since its 2017 listing, citing prolonged losses and pandemic disruptions, but said operational improvements and selective expansion should support a recovery in performance and long-term value creation.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10